Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Accelererad bilateral rTMS på geriatrisk depression

15 november 2026 uppdaterad av: National Taiwan University Hospital

Terapeutisk effekt av accelererad bilateral upprepad transkraniell magnetisk stimulering på geriatrisk depression: en prospektiv dubbelblind, randomiserad kontrollerad studie

This study aims to evaluate the efficacy of accelerated bilateral repetitive transcranial magnetic stimulation (rTMS) on major depression, anxiety, cognitive function and physiological parameters in elderly depressive patients.

Studieöversikt

Detaljerad beskrivning

Repeated transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation treatment, showing good therapeutic effect to medicine treatment-refractory patients. Recent studies suggested bilateral DLPFC might be effective to geriatric depression. Accelerated treatment course was reported to have similar therapeutic effect and safety profile with traditional course. The investigators hypothesize accelerated bilateral rTMS is effective to geriatric depression and comorbid anxiety.

Cognitive impairment and decreased parasympathetic tone are common in patients with major depression. The investigators hypothesize cognitive function and physiological indicators improve after accelerated bilateral rTMS.

In this single-center, prospective double-blind, randomized, active-controlled trial, the investigators aim to recruit 100 patients older than 60 years, without neurocognitive disorders, and refractory to one or more antidepressants. The experimental group would receive an rTMS course with high-frequency stimulation at left DLPFC followed by low-frequency inhibition at right DLPFC, two sessions daily, five days a week, and two weeks in total. The standard treatment group would receive an rTMS course with high-frequency stimulation at left DLPFC as standard treatment parameters. Mood, cognition and physiological markers would be monitored every week. The primary outcome is response and remission rate of major depression measured by Hamilton Rating Scale for Depression.

Studietyp

Interventionell

Inskrivning (Faktisk)

2

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Douliu, Taiwan
        • Department of Psychiatry, National Taiwan University Hospital, Yun-Lin Branch

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

60 år till 85 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • age between 60-85 years
  • literate and received basic education for at least 2 years
  • diagnosis of major depressive disorder, without psychotic features, according to DSM-5
  • have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale
  • failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks
  • psychoactive agents were in stable doses before randomization

Exclusion Criteria:

  • active suicide plans or attempts; or suicide attempts in the last 12 months
  • diagnosis of schizophrenia or bipolar disorder according to DSM-5
  • have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months
  • have delirium, major neurocognitive disorder or MMSE < 24
  • current use of bupropion >300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines
  • history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases
  • with a cardiac pacemaker or defibrillator
  • received rTMS treatment before

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Experimental Group

The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.

Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Aktiv komparator: Standard Treatment Group

The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.

Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)
Tidsram: day 1, day 5, day 12, day 19

HAM-D 17 is a scale rating the severity of depression, covering emotional, cognitive and somatic symptoms of depression. Higher scores indicate higher severity. Response to treatment is defined as ≥ 50% decrease in HAM-D 17; remission is defined as ≤ 7 points in HAM-D 17.

day 1, day 5, day 12, day 19

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Degree of Change in Hamilton Anxiety Rating Scale (HAM-A)
Tidsram: day 1, day 5, day 12, day 19

HAM-A is a scale rating the severity of anxiety, covering emotional, cognitive and somatic symptoms of anxiety. Higher scores indicate higher severity.

day 1, day 5, day 12, day 19
Degree of Change in Mini-Mental State Examination (MMSE)
Tidsram: day 1, day 5, day 12, day 19

MMSE is a wildly-used tool to evaluate several cognitive function domains.

day 1, day 5, day 12, day 19
Degree of Change in Stroop Test
Tidsram: day 1, day 5, day 12, day 19

Task 1 (word phase) requests a subject to say a color name string (red, green, blue) printed in black; Task 2 (color phase) requests a subject to say the printed colors (red, green, blue) of letter "x" string; Task 3 (interference phase) requests a subject to say the printed colors of a string of color names (red, green, blue).

day 1, day 5, day 12, day 19
Degree of Change in Trail Making Test
Tidsram: day 1, day 5, day 12, day 19

Task 1 requests a subject to connect a sequence of 25 consecutive numbers regardless of their colors; Task 2 requires a subject to connect 25 consecutive numbers in alternative colors.

day 1, day 5, day 12, day 19
Degree of Change in Verbal Fluency Test
Tidsram: day 1, day 5, day 12, day 19

This test requests a subject to speak as many names of vegetables, fishes or fruit as possible in 45 seconds.

day 1, day 5, day 12, day 19
Degree of Change in Physiological Parameters
Tidsram: day 1, day 5, day 12, day 19

ProComp5 Infiniti (SA7525) Biofeedback System would be used. Heart rate variability, skin conductance, body temperature and respiratory rate would be measured.

day 1, day 5, day 12, day 19

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 november 2020

Primärt slutförande (Faktisk)

21 december 2022

Avslutad studie (Faktisk)

21 december 2022

Studieregistreringsdatum

Först inskickad

15 juli 2020

Först inskickad som uppfyllde QC-kriterierna

22 juli 2020

Första postat (Faktisk)

24 juli 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 november 2026

Senast verifierad

1 maj 2021

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera